Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$7.72
-0.5%
$11.33
$2.08
▼
$15.37
$3.56B0.8815.65 million shs1.51 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,456.71
+0.9%
$1,242.25
$850.51
▼
$1,475.25
$1.37T0.42.95 million shs664,305 shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$167.11
-0.2%
$148.58
$122.14
▼
$186.12
$16.88B0.361.24 million shs127,364 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$41.97
+0.8%
$40.09
$35.12
▼
$64.16
$187.02B0.716.28 million shs7.16 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$27.86
-4.7%
$29.33
$23.82
▼
$43.10
$3.54B0.793.32 million shs632,289 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%-3.48%-43.02%+9.30%+214.17%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+5.24%+14.79%+21.92%+40.93%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
0.00%+1.68%+23.35%+8.36%+15.56%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+3.18%+7.42%-7.21%-13.62%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%+8.87%+16.09%-13.11%-25.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$7.72
-0.5%
$11.33
$2.08
▼
$15.37
$3.56B0.8815.65 million shs1.51 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,456.71
+0.9%
$1,242.25
$850.51
▼
$1,475.25
$1.37T0.42.95 million shs664,305 shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$167.11
-0.2%
$148.58
$122.14
▼
$186.12
$16.88B0.361.24 million shs127,364 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$41.97
+0.8%
$40.09
$35.12
▼
$64.16
$187.02B0.716.28 million shs7.16 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$27.86
-4.7%
$29.33
$23.82
▼
$43.10
$3.54B0.793.32 million shs632,289 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%-3.48%-43.02%+9.30%+214.17%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+5.24%+14.79%+21.92%+40.93%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
0.00%+1.68%+23.35%+8.36%+15.56%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+3.18%+7.42%-7.21%-13.62%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%+8.87%+16.09%-13.11%-25.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.71
Moderate Buy$13.8078.76% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,422.00-2.38% Downside
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.88
Moderate Buy$202.5921.23% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.00
Hold$59.4441.63% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.79
Moderate Buy$93.36235.12% Upside

Current Analyst Ratings Breakdown

Latest IOVA, NBIX, VKTX, NVO, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,400.00 ➝ $1,550.00
11/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B) ➝ Buy (B+)
11/13/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetEqual Weight$185.00 ➝ $191.00
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/6/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Boost Price TargetOverweight$18.00 ➝ $19.00
11/6/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Boost Price TargetMarket Outperform$8.00 ➝ $12.00
11/4/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetBuy$207.00 ➝ $224.00
11/3/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Boost Price TargetNeutral$7.00 ➝ $8.00
11/3/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetEqual Weight$183.00 ➝ $185.00
11/3/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetOutperform$187.00 ➝ $190.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$263.50M13.55N/AN/A$1.76 per share4.39
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$86.46B15.85$25.37 per share57.42$28.07 per share51.90
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$3.70B4.57$5.00 per share33.40$32.63 per share5.12
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$333.65B0.56$4.73 per share8.88$6.58 per share6.38
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$5.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$390.98M-$0.53N/AN/AN/A-58.20%-29.71%-23.55%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8147.2728.731.7331.90%86.76%22.03%2/3/2027 (Estimated)
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$478.60M$6.7424.7416.900.6818.98%23.39%16.22%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$3.9710.5512.161.4333.99%53.52%19.49%2/3/2027 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$5.40N/AN/AN/AN/A-117.35%-88.87%N/A

Latest IOVA, NBIX, VKTX, NVO, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.09-$0.05+$0.04-$0.05$115.98 million$121.47 million
11/2/2026Q3 2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$1.91$3.29+$1.38$1.96$1.04 billion$1.12 billion
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
10/28/2026Q3 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.06-$1.55-$0.49-$1.55N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.48%+15.18%22.46%11 Years
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.811.94%+21.74%20.40%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest IOVA, NBIX, VKTX, NVO, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
5.20
4.67
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
2.04
1.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.54
0.84
0.64
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.43
7.27
7.27
CompanyEmployeesShares OutstandingFree FloatOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
975462.65 million426.57 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.75 million939.43 millionOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2,000101.22 million96.56 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
74127.52 million120.76 millionOptionable

Recent News About These Companies

Viking Therapeutics stock trades at EUR 25.68 on Thursday
Viking Therapeutics stock trades at 26.00 euros Tuesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$7.72 -0.04 (-0.52%)
As of 10:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,456.71 +13.21 (+0.92%)
As of 10:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$167.11 -0.29 (-0.17%)
As of 10:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$41.97 +0.34 (+0.81%)
As of 10:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$27.86 -1.36 (-4.65%)
As of 10:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.